Abstract:Berberine, a well-known alkaloid, has been proved to possess various pharmacological activities. Previous studies demonstrated that berberine could be extensively metabolized and the metabolites also contributed to its therapeutic effects. However, as for berberine’s metabolites, especially phase II metabolites, pharmacokinetics and excretion studies were rarely reported. The objective of this study was to thoroughly investigate the pharmacokinetic and excretion profiles of berberine and its nine metabolites, namely, berberrubine (M1), demethyleneberberine (M2), jatrorrhizine (M3), jatrorrhizine-3- O-β -D-glucuronide (M4), jatrorrhizine-3- O -sulfate (M5), thalfendine-10- O-β -D-glucuronide (M6), berberrubine-9- O-β -D-glucuronide (M7), demethyleneberberine-2- O -sulfate (M8) and demethyleneberberine-2- O-β -D-glucuronide (M9) in rats. An accurate and reliable LC-MS/MS method was developed and validated for the determination of berberine and its nine metabolites in rat biosamples. Pharmacokinetic profiles of berberine and its nine metabolites were obtained after a single intravenous administration (4.0 mg/kg) and oral administration (48.2, 120 or 240 mg/kg) of berberine in rats. For excretion study, rats were intragastrically administered a single dose of 48.2 mg/kg berberine. Our results showed that berberine could be metabolized rapidly and all the nine metabolites could be detected in vivo . The absolute bioavailability of berberine was 0.37 ± 0.11%. As for the AUC 0–48 h values, phase II metabolites were much higher than those of phase I metabolites, suggesting that phase II metabolites were the major metabolites exist in blood circulation. 18.6% of the berberine was excreted in feces as berberrubine (M1). The total recovery of berberine and its nine metabolites from urine, bile and feces was 41.2%. This is the first systematic study about the pharmacokinetics and excretion of berberine and its nine metabolites, which will be beneficial for both better understanding the clinical effects and further development of berberine.

Absorption Enhancement of Sodium Caprate on Berberine in Intestine of Rats

Influence of coptis Chinensis on pharmacokinetics of flavonoids after oral administration of radix Scutellariae in rats.

Study on Absorption Kinetics of Phenolic Alkaloids from Menispermum Dauricum in Rats' Intestines

Pharmacokinetics of Berberine in Rat Intestinal and Bile Following Intravenous Administration of Coptidis Rhizoma Extract

Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats.

Pharmacological actions of cannabinoids.

Pharmacokinetic difference of berberine between normal and chronic visceral hypersensitivity irritable bowel syndrome rats and its mechanism

Characterization Of The Transportation Of Berberine In Coptidis Rhizoma Extract Through Rat Primary Cultured Cortical Neurons

Studies on pharmacokinetic properties and intestinal absorption mechanism of sanguinarine chloride: in vivo and in situ

In situ Intestinal Absorption Kinetics of Carvedilol Nanosuspensions in Rats

Gastrointestinal Absorption and Biotransformation of Bufadienolides in Rats by HPLC/MS

Berberine ameliorates colonic damage accompanied with the modulation of dysfunctional bacteria and functions in ulcerative colitis rats

Pharmacokinetics and Excretion of Berberine and Its Nine Metabolites in Rats

Absorption of Coptisine Chloride and Berberrubine Across Human Intestinal Epithelial by Using Human Caco-2 Cell Monolayers

Effect of berberine on pharmacokinetics and pharmacodynamics of atorvastatin in hyperlipidemia rats

Investigation of the Mechanisms of Improved Oral Bioavailability of Bergenin Using Bergenin–phospholipid Complex

[Study on the tissue distribution of berberine from Rhizoma Coptidis and compatibility with Rhizoma Coptidis and Cortex Cinnamomi in rats].

Scene Change Detection Using Shape Information in MPEG-4 Compressed Domain

Absorptive Profile of Chlorogenic Acid in Rats.

[Berberine Action Targets and Its Absorption Behavior：how to Use Old Drug for New Mechanisms].

Pharmacokinetic studies of novel berberine derivatives with ultra-performance liquid chromatography-tandem mass spectrometry